Corient Private Wealth
BBIO icon

Corient Private Wealth’s BridgeBio Pharma BBIO Stock Holding History

Corient Private Wealth’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
23,950
-329
-1% -$23K ﹤0.01% 1457
2026
Q1 		$1.08M Buy
24,279
+7,843
+48% +$568K ﹤0.01% 1623
2025
Q4 		$1.26M Sell
16,436
-811
-5% -$53.2K ﹤0.01% 1387
2025
Q3 		$896K Buy
17,247
+2,353
+16% +$115K ﹤0.01% 1478
2025
Q2 		$643K Buy
+14,894
New +$542K ﹤0.01% 1575
2025
Q1 		– Sell
-19,259
Closed -$967 – 2294
2024
Q4 		$967 Sell
19,259
-104
-0.5% -$2.69K ﹤0.01% 2343
2024
Q3 		$493K Buy
19,363
+120
+0.6% +$3.15K ﹤0.01% 1737
2024
Q2 		$487K Hold
19,243
– – ﹤0.01% 1651
2024
Q1 		$595K Hold
19,243
– – ﹤0.01% 1547
2023
Q4 		$777K Hold
19,243
– – ﹤0.01% 1392
2023
Q3 		$507K Sell
19,243
-16,000
-45% -$454K ﹤0.01% 1492
2023
Q2 		$606K Hold
35,243
– – ﹤0.01% 1357
2023
Q1 		$584K Buy
35,243
+2,000
+6% +$23.3K ﹤0.01% 1309
2022
Q4 		$253K Buy
+33,243
New +$318K ﹤0.01% 1401

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Corient Private Wealth's BBIO Position: Q2 2026 in Review

Corient Private Wealth reduced its BridgeBio Pharma (BBIO) stake by 1.4% in Q2 2026, selling an estimated $23K and leaving 23,950 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1457.

Corient Private Wealth first reported a position in BBIO in Q4 2022 and has held it in 14 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Corient Private Wealth held 23,950 shares of BridgeBio Pharma worth $1.78M as of Q2 2026.
  • Corient Private Wealth sold 329 BridgeBio Pharma shares in Q2 2026, an estimated $23K.
  • BridgeBio Pharma made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1457 holding.
  • Corient Private Wealth first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 14 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.